Unoprostone

Drug Profile

Unoprostone

Alternative Names: Isopropyl unoprostone; Ocuseva; Rescula; UF-021; Unoprostone isopropyl 0.12%

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator R-Tech Ueno Ltd
  • Developer R-Tech Ueno Ltd; Santen Pharmaceutical; Sucampo Pharmaceuticals
  • Class Antiglaucomas; Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide stimulants; Potassium channel agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase III Retinitis pigmentosa
  • No development reported Age-related macular degeneration

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Japan (Topical, Drops)
  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc
  • 04 Jan 2017 Launched for Ocular hypertension in Japan (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top